Values First Advisors Inc. Has $407,000 Stake in Royalty Pharma plc (NASDAQ:RPRX)

Values First Advisors Inc. grew its position in Royalty Pharma plc (NASDAQ:RPRX) by 53.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,963 shares of the biopharmaceutical company’s stock after buying an additional 5,551 shares during the quarter. Values First Advisors Inc.’s holdings in Royalty Pharma were worth $407,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in RPRX. Franklin Resources Inc. increased its stake in Royalty Pharma by 5.0% in the third quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company’s stock valued at $40,705,000 after acquiring an additional 70,130 shares during the last quarter. Van ECK Associates Corp boosted its holdings in shares of Royalty Pharma by 171.1% in the 3rd quarter. Van ECK Associates Corp now owns 101,500 shares of the biopharmaceutical company’s stock valued at $2,777,000 after purchasing an additional 64,057 shares in the last quarter. Summit Global Investments bought a new position in shares of Royalty Pharma in the 3rd quarter valued at $735,000. Pallas Capital Advisors LLC acquired a new position in shares of Royalty Pharma during the 4th quarter worth $2,355,000. Finally, Two Sigma Advisers LP lifted its position in shares of Royalty Pharma by 44.7% during the 3rd quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock worth $85,809,000 after buying an additional 936,900 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on RPRX. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. Finally, Citigroup dropped their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, October 25th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $41.67.

Royalty Pharma Stock Performance

NASDAQ:RPRX opened at $32.34 on Thursday. The stock’s 50-day moving average is $28.05 and its 200-day moving average is $27.68. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $32.72. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. The stock has a market cap of $19.05 billion, a P/E ratio of 16.76 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 50.53% and a return on equity of 24.65%. Equities research analysts anticipate that Royalty Pharma plc will post 4.08 earnings per share for the current year.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 2.72%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date is Friday, February 21st. Royalty Pharma’s dividend payout ratio is presently 43.52%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.